ESRRA and breast carcinoma: Together, these data indicated that NRF2 may regulate RhoA expression by inhibiting the expression of ERR1 through its binding to ERR1 promoter region as a silencer, and thus preventing ERR1-mediated degradation of RhoA to further activate a critical signal transduction pathway of RhoA to drive breast cancer progression.